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The mucopolysaccharidoses (MPS) are a heterogeneous group of inborn errors of lysosomal glycosaminoglycan (GAG)
metabolism. The importance of this group of disorders among the inborn errors of metabolism led us to report 19 cases.
Method: We performed clinical, radiological, and biochemical evaluations of the suspected patients, which allowed us to
establish a definite diagnosis in 19 cases.
Results: Not all patients showed increased GAG levels in urine; enzyme assays should be performed in all cases with strong
clinical suspicion. The diagnosis was made on average at the age of 48 months, and the 19 MPS cases, after a full clinical, radiological,
and biochemical study, were classified as follows: Hurler – MPS I (1 case); Hunter – MPS II (2 cases); Sanfilippo – MPS III (2
cases); Morquio – MPS IV (4 cases); Maroteaux-Lamy – MPS VI (9 cases); and Sly – MPS VII (1 case).
Discussion: The high relative frequency of Maroteaux-Lamy disease contrasts with most reports in the literature and could
express a population variability.
DESCRIPTORS: Mucopolysaccharidoses. Glycosaminoglycans. Lysosomal storage diseases.
The mucopolysaccharidoses (MPS)
are a heterogeneous group of lysoso-
mal storage disorders caused by the de-
ficiency of enzymes involved in deg-
radation of glycosaminoglycans, also
named mucopolysaccharides. Its pat-
tern of inheritance is autosomal reces-
sive, except for MPS II, which is X-
linked. The incidence of MPS may be
as high as 1:10 000 live births, and
Hurler syndrome is usually reported in
the literature as the most frequently
occurring type1,2.
There are at least 10 enzymes
known to be required for the stepwise
degradation of dermatan sulfate,
heparan sulfate, keratan sulfate, and
chondroitin sulfate, deficiencies of
which lead to a wide spectrum of a
progressive and chronic clinical disor-
ders (Table 1).
The importance of this group of
disorders among the inborn errors of
metabolism led us to report 19 MPS
cases after clinical, radiological, and
biochemical investigations, which al-
lowed us to establish the definitive di-
agnosis.
PATIENTS AND METHODS
The study was carried out over a
period of six years (1994-1999). We
could establish the definitive diagnosis,
including the specific type of MPS, in
19 patients.
The main features observed were:
normal appearance at birth with a
progressive coarse facies, progressive
neurological deterioration, corneal
clouding, gibbous lumbar vertebrae,
hirsutism, joint contractures, hepa-
tosplenomegaly, short stature, and skel-
etal, respiratory, and cardiac abnor-
malities, with a characteristic pattern of
a chronic and progressive disorder. Ra-
diological and ophthalmologic studies
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were indicated for all patients sus-
pected.
A biochemical investigation was
carried out according to the proposal of
Leistner and Giugliani3, in suspected
patients. Initially, the glycosaminogly-
can (GAG) concentration in urine was
measured, and the relative proportion
of their components (dermatan sulfate,
heparan sulfate, chondroitin sulfate,
and keratan sulfate) was estimated.
The diagnostic enzyme assays were
selected according to clinical suspicion
and results of the biochemical investi-
gation.
RESULTS
The biochemical investigation al-
lowed the diagnosis of 19 MPS cases,
classified as follows: Hurler – MPS I
(1 case – 5.3%); Hunter – MPS II (2
cases – 10.5%); Sanfilippo – MPS III
(2 cases – 10.5%; all type B); Morquio
– MPS IV (4 cases – 21.1 %; all type
A); Maroteaux-Lamy – MPS VI (9
cases – 47.4%) and Sly – MPS VII (1
case – 5.3%) (Fig. 1-5).
The average age at diagnosis was
48 months (ranging from 7 to 19
years), and the patients’ ages ranged
from 2 to 20 years.
Parental consanguinity was ob-
served in 6 cases. Thirteen cases were
sporadic, being the reminiscent familial.
Most patients presented coarse fa-
cial features (16/19 – 84%) and
hepatosplenomegaly (12/19 – 63%).
The frequency of obstructive airway
disease was 53%, and corneal clouding
was observed in 37%; gibbous lumbar
vertebrae occurred in 58% of the cases,
and joint stiffness occurred in 74%.
Cardiac abnormalities were ob-
served in 9 cases (47%), including car-
diac murmur (4/9 – 44%), mitral and
tricuspid valvar reflux (2/9 – 22%), and
septal defects (2/9 – 22%). A pericar-
dium effusion (1/9 –11%) was ob-
served in 1 case of Hurler syndrome.
Skeletal abnormalities were evident
in 16 out of 18 cases radiologically
studied (89%). We found the following
main radiological findings: “J-shaped”
sella turcica, dorsal kyphosis, broad
and saber-shaped ribs, wedge-shaped
beaking abnormality of the vertebral
body, osteoporosis, increased diameter
of tubular bones, angulation of the dis-
tal end of the radius and ulna, narrow-
ing of the proximal metacarpals, de-
layed carpal bone age, and hip abnor-
Table 1 - Classification of the mucopolysaccharidoses.
MPS TYPE EPONYM ENZYME DEFECT
I Hurler -L-iduronidase
II Hunter Iduronate 2-sulfatase
III-A Sanfilippo type A Heparan N-sulfatase
III-B Sanfilippo type B -N-acetylglucosaminidase
III-C Sanfilippo type C Acetyl-CoA:  glucosaminide N-acetyltransferase
III-D Sanfilippo type D N-acetylglucosamine 6-sulfatase
IV-A Morquio type A Galactose 6-sulfatase
IV-B Morquio type B -galactosidase
VI Maroteaux-Lamy N-acetylgalactosamine 4-sulfatase
VII Sly -glucuronidase
Figure 1 - MPS patient: Type I (1y).
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Figure 2 - MPS patient: Type II (5y).
Figure  3  -  Two  brothers  with  MPS  type  III-B  (8y,13y).
Figure 4 -  MPS patient:  Type IV-A (4y).
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malities as a constriction above the ac-
etabulum.
Developmental delay, a feature
present in 42% of the cases (8/19), was
observed in the Hurler, Hunter, and
Sanfilippo cases, and also in 2
Maroteaux-Lamy cases.
The clinical, radiological, and bio-
chemical results are summarized in
table 2.
DISCUSSION
The most frequent type of MPS is
reported to be Hurler syndrome (MPS
type I) with an estimated frequency of
1:50 000 to 1:132 0001,4,5,6,7. This fig-
ure is probably underestimated, due to
early deaths and diagnostic difficulties.
Hunter syndrome is also reported to be
frequent, but with lower incidence than
Hurler syndrome. The clinical fre-
quency of Morquio syndrome seems to
be lower than that of Hurler and Hunter
syndromes4.
Sanfilippo syndrome ranks among
the most common types of MPS1. As
there are not striking physical features
accompanying the marked mental re-
tardation of the Sanfilippo syndrome,
Neulfeld and Muenzer (1995)2 believe
that it is under diagnosed, considering
the high incidence found in the Neth-
erlands (1:24 000 live births) as a re-
sult of the efforts employed to detect
all cases.
Table 2 - Clinical, laboratory and radiologic findings in 19 patients.
Type SS MD Coarse CO Visc Gib JS Hirs Card Skel GAGS Enzymatic defect
I Hurler + + + + H/S + + + + +  -L-iduronidase
II Hunter - + + - H - + + - +  Iduraonate 2-sulfatase
II Hunter + + + - H/S + + + + +  Iduraonate 2-sulfatase
III-B Sanfilippo - + + - H/S -  - - - - normal -N-acetylglucosaminidase
III-B Sanfilippo - + + - H/S -  - - - - § -N-acetylglucosaminidase
IV-A Morquio - - + +  - +  - - + +  Galactose 6-sulfatase
IV-A Morquio + - - -  - - + - - + normal Galactose 6-sulfatase
IV-A Morquio + - - -  - - + - - + normal Galactose 6-sulfatase
IV-A Morquio + - - -  - +  - - - + normal Galactose 6-sulfatase
VI Maroteaux-Lamy + - + - H/S + + + + +  N-acetylgalactosamine sulfatase
VI Maroteaux-Lamy + - + - H/S - + + + +  N-acetylgalactosamine ulfatase
VI Maroteaux-Lamy + - + - H/S + + + + +  N-acetylgalactosamine sulfatase
VI Maroteaux-Lamy + - + + H/S + + + - + Normal N-acetylgalactosamine sulfatase
VI Maroteaux-Lamy - + + + H/S + + + - +  N-acetylgalactosamine sulfatase
VI Maroteaux-Lamy - + + + H/S + + + - +  N-acetylgalactosamine sulfatase
VI Maroteaux-Lamy + - + + H/S - + + + +  N-acetylgalactosamine sulfatase
VI Maroteaux-Lamy + - + + - + + + + +  N-acetylgalactosamine sulfatase
VI Maroteaux-Lamy - - + - H/S + + + + +  N-acetylgalactosamine sulfatase
VII Sly + + + - H/S - - - - § § -glucuronidase
Abrev: SS = short stature; MD = mental delay; Coarse = Coarse facies; CO = Corneal opacity; Visc = visceromegaly; Gib = gibbous vertebrae; JS =
joint stiffness; Hirs = hirsutism; Card = cardiac abnormalities; Skel = skeletal abnormalities; § = not performed.
H/S = Hepatomegaly/Splenomegaly
Figure 5 - MPS patients: Type VI (5y,17y).
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MPS type VI, known as
Maroteaux-Lamy syndrome, does not
have good estimates of its frequency,
as it seems to be rare in most reports
and as a considerable number of indi-
viduals with Hurler-Scheie syndrome
were classified in the past as having
Maroteaux-Lamy syndrome 1.
Our results, in contrast to the litera-
ture1,4,5,6,7,8,9, show a high proportion of
Maroteaux-Lamy cases (47%). As
there are few reports about MPS inci-
dence in Brazil10,11, we believe that this
significant proportion of MPS VI cases
could be caused by population charac-
teristics.
Our clinical investigation (Table 2)
revealed short stature in 12/19 cases
(63%) and normal growth in 7 patients:
1/2 Hunter; 2/2 Sanfilippo; 1/4
Morquio; 3/9 Maroteaux-Lamy. The
finding of abnormalities in the skeletal
evaluation was the most consistent
finding in all MPS types: 16/18 cases
(88%), sparing only the 2 Sanfilippo
patients.
Coarse facies was observed in 16/
19 cases (84 %), (the exceptions were
three Morquio patients). Hepatosple-
nomegaly was detected in 14/19 cases
(73%), not being found in 1
Maroteaux-Lamy case and in the 4
Morquio patients. Corneal opacity was
observed in 7/19 cases (36%), and car-
diac involvement was observed in 9/19
patients (47%).
Mental retardation was present in 8/
19 cases (42%). Normal intelligence
was present in all Morquio patients and
7/9 Maroteaux-Lamy cases (77%).
Clinical and radiological findings
are fundamental for the diagnosis of a
MPS disorder. However, investigation
of glycosaminoglycans and enzymatic
studies are essential not only to estab-
lish the definitive diagnosis but also to
classify exactly the MPS type – infor-
mation very useful for genetic counsel-
ing and prenatal diagnosis.
The finding of normal urinary GAG
levels in 5/17 patients (29%) is an in-
dication that a normal urinary GAG
pattern does not rule out the possibil-
ity of a MPS disorder.
Diagnosis is not always easy, and
confirmation is based on specific enzy-
matic investigation. Therefore, both
physicians and laboratory personnel
should contribute their experience to a
complete study of cases with a sus-
pected MPS disorder, in order to con-
duct a rapid and through investigation
to reach an accurate diagnosis.
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As mucopolissacaridoses (MPS)
constituem um grupo de erros inatos
do metabolismo lisossomal dos glico-
saminoglicanos (GAG) bastante hete-
rogêneo. A importância das MPS le-
vou-nos a relatar as características de
19 casos.
Método: Realizamos uma avalia-
ção clínica, radiológica e bioquímica,
incluindo estudos enzimáticos, que nos
permitiram estabelecer o diagnóstico
definitivo em 19 casos.
Resultados: Nem todos os pacien-
tes apresentaram níveis elevados de
GAG na urina, devendo os ensaios
enzimáticos serem realizados em todos
os pacientes com forte suspeita clíni-
ca. O diagnóstico foi estabelecido em
média aos 48 meses de idade e os ca-
sos, após amplo estudo clínico, radio-
lógico e bioquímico, foram classifica-
dos como: Hurler – MPS I (1 caso);
Hunter – MPS II (2 casos); Sanfilippo
– MPS III (2 casos); Morquio – MPS
IV (4 casos); Maroteaux-Lamy – MPS
VI (9 casos); e Sly – MPS VI (1 caso).
Discussão: A proporção relativa-
mente alta de MPS VI (Maroteaux-
Lamy) contrasta com a maioria dos da-




ças lisossômicas de depósito.
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